From: The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study
 | Charlson Comorbidity score | ||
---|---|---|---|
 | 0 | 1–2 | 3+ |
N (%) | 3,727 (72%) | 1,116 (21%) | 370 (7%) |
1-year | Â | Â | Â |
   Survival in % | 73 (71–74) | 58 (55–60) | 44 (39–49) |
   MRR | 1 (ref.) | 1.8 (1.6–2.0) | 2.7 (2.3–3.1) |
   Adj. MRR* | 1 (ref.) | 1.4 (1.2–1.5) | 2.0 (1.7–2.3) |
   Adj. MRR** | 1 (ref.) | 1.3 (1.2–1.5) | 1.8 (1.6–2.1) |
5-year | Â | Â | Â |
   Survival in % | 37 (36–39) | 24 (21–27) | 12 (8–16) |
   MRR | 1 (ref.) | 1.5 (1.4–1.6) | 2.3 (2.1–2.6) |
   Adj. MRR* | 1 (ref.) | 1.3 (1.2–1.4) | 1.8 (1.6–2.1) |
   Adj. MRR** | 1 (ref.) | 1.2 (1.1–1.4) | 1.7 (1.5–1.9) |